- Home
- SOFI vs PCVX Comparison
SOFI vs PCVX Comparison
Compare SOFI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOFI
- PCVX
- Stock Information
- Founded
- SOFI 2011
- PCVX 2013
- Country
- SOFI United States
- PCVX United States
- Employees
- SOFI N/A
- PCVX N/A
- Industry
- SOFI Diversified Financial Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SOFI Finance
- PCVX Health Care
- Exchange
- SOFI Nasdaq
- PCVX Nasdaq
- Market Cap
- SOFI 11.9B
- PCVX 4.4B
- IPO Year
- SOFI N/A
- PCVX 2020
- Fundamental
- Price
- SOFI $18.89
- PCVX $32.94
- Analyst Decision
- SOFI Buy
- PCVX Strong Buy
- Analyst Count
- SOFI 14
- PCVX 10
- Target Price
- SOFI $14.15
- PCVX $136.50
- AVG Volume (30 Days)
- SOFI 72.4M
- PCVX 1.5M
- Earning Date
- SOFI 07-29-2025
- PCVX 08-05-2025
- Dividend Yield
- SOFI N/A
- PCVX N/A
- EPS Growth
- SOFI N/A
- PCVX N/A
- EPS
- SOFI 0.43
- PCVX N/A
- Revenue
- SOFI $2,771,415,000.00
- PCVX N/A
- Revenue This Year
- SOFI $26.36
- PCVX N/A
- Revenue Next Year
- SOFI $19.40
- PCVX N/A
- P/E Ratio
- SOFI $42.87
- PCVX N/A
- Revenue Growth
- SOFI 23.62
- PCVX N/A
- 52 Week Low
- SOFI $6.01
- PCVX $27.66
- 52 Week High
- SOFI $18.92
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SOFI 72.65
- PCVX 46.08
- Support Level
- SOFI $14.64
- PCVX $32.06
- Resistance Level
- SOFI $15.64
- PCVX $33.81
- Average True Range (ATR)
- SOFI 0.62
- PCVX 1.23
- MACD
- SOFI 0.21
- PCVX -0.12
- Stochastic Oscillator
- SOFI 96.35
- PCVX 19.86
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.